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Abstract
A summit on cellular therapy for cancer discussed and presented advances related to the use of adoptive cellular
therapy for melanoma and other cancers. The summit revealed that this field is advancing rapidly. Conventional
cellular therapies, such as tumor infiltrating lymphocytes (TIL), are becoming more effective and more available.
Gene therapy is becoming an important tool in adoptive cell therapy. Lymphocytes are being engineered to
express high affinity T cell receptors (TCRs), chimeric antibody-T cell receptors (CARs) and cytokines. T cell subsets
with more naïve and stem cell-like characteristics have been shown in pre-clinical models to be more effective
than unselected populations and it is now possible to reprogram T cells and to produce T cells with stem cell
characteristics. In the future, combinations of adoptive transfer of T cells and specific vaccination against the
cognate antigen can be envisaged to further enhance the effectiveness of these therapies.
Background
A summit on cellular therapy for cancer was held on
November 1 and 2, 2011 at the NIH in Bethesda, Mary-
land. Advances related to the use of adoptive cellular
therapy for melanoma and other cancers were presented
and discussed and are summarized in this review.
Tumor infiltrating lymphocytes (TIL)
Treatment of melanoma with tumor infiltrating lympho-
cyte (TIL) cells of high functional avidity has been
improved by treating patients with lymphocyte reducing
chemotherapy prior to the administration of the TIL
cells. Preconditioning the TIL recipient with non-mye-
loablative chemotherapy has resulted in a objective clini-
cal response rate of 49% with 13% complete responses
and preconditioning with non-myeloablative chemother-
apy plus 12 Gy total body irradiation (TBI) further
improved objective clinical response rate to 72% with
40% complete responses [1].
Several advancements associated with manufacture of
TIL have been made and as a result TIL production has
become more practical. Traditionally, initial TIL cultures
were screened for reactivity to tumor antigens and only
the reactive cultures were selectively expanded. Many
cell processing laboratories are no longer screening
initial TIL colonies for tumor-reactive cells, rather, they
are expanding all isolated TIL cells based on the initial
finding that nearly 80% of TILs possess autologous
tumor reactivity [2] This has reduced the duration of
time that TIL spend in culture and as a result these
cells are known as “young” TIL. Clinical studies are
evaluating whether that young TIL are as effective as
TIL produced using traditional methods [3].
TIL have been traditionally manufactured using tissue
culture plates for initial culture and flasks and bags for
rapid expansion protocols (REP). This process, however,
results in large final culture volumes: 30 to 60 liters.
These large volumes are associated with the use large
quantities of media, cytokines, and additives. In addition,
harvesting these large volumes is time consuming. In
order to simplify and reduce the quantity of reagents
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and labor associated with TIL production, two new
methods are being tested for TIL REP; bioreactors and
gas permeable flasks. The WAVE bioreactor can be
used for TIL REP [4]. The volume of the final TIL pro-
duct is reduced by the WAVE bioreactor, but the
WAVE requires the investment of capital and specia-
lized staff training. The volume of media required for
TIL REP can also be reduced by using gas permeable
flasks [5]. The flasks are simple to use and do not
require capital investment. In addition, gas permeable
flasks can also be used for initial TIL culture.
The increased clinical effectiveness and improved pro-
duction methods are leading to the more widespread
use of TIL to treat patients with melanoma.
Engineered T cells
While TIL Therapy is effective, melanoma samples can-
not be obtained for TIL production from all patients
and, in some cases, TIL cannot be isolated from the
resected tumor. Engineered T cells are being used
increasingly for patients from whom TIL are not avail-
able. Two general approaches involving engineered T
cells are being used clinically. Both involve the use of
autologous peripheral blood T cells; one involves gene
transfer of high affinity T cell receptors (TCR) and the
other gene transfer of chimeric antibody-T cell receptors
(CAR) [6].
Patients with melanoma have been treated with T cells
engineered using recombinant retroviral vectors to
express HLA-2 restricted high affinity T cell receptors
(TCRs) specific for melanoma antigens MART-1 and
gp100 [7,8]. While patients treated with these engi-
neered autologous cells have had objective clinical
responses, some patients have experienced autoimmune
responses due to the destruction of normal melanocytes
in the skin, eyes and ears [8]. Another adoptive cellular
therapy approach utilizing engineered T cells involves
the use of TCRs specific for cancer testis antigens that
are expressed by fetal tissue and cancer, but not by
adult cells, such as NY-ESO-1. NY-ESO-1 is expressed
by 10 to 50% of metastatic melanomas, 80% of synovial
cell sarcomas and breast, prostate, thyroid and ovarian
cancers [6]. TCRs specific for NY-ESO-1 have been
used to treat patients with melanoma and sarcoma and
have resulted in objective clinical responses in 5 of 11
melanoma patients and 4 of 6 synovial sarcoma patients
[9]. Protocols are also being developed that involve gene
transfer of vectors encoding IL-12 and MAGE-A3 speci-
fic TCRs.
Another approach involves the transduction of autolo-
gous T cells to express CARs made up of the variable
region a tumor specific antibody fused to an intracellu-
lar signaling domain capable of activating T cells. Typi-
cally, a CAR is comprised of an extracellular scFv
portion of a monoclonal antibody and an intracellular
CD3 zeta chain in tandem with a co-stimulatory signal-
ing domain, such as CD28. In addition, some CARs
include other stimulatory factors such as 4-1BB or OX-
40, alone or in combination with CD28 [6]. Since CARs
have the specificity of a monoclonal antibody, they are
not HLA restricted and they can be used to treat any
patient whose tumor expresses the antigen to which the
monoclonal antibody is directed. Autologous T cells
engineered to express anti-CD19 CAR have been effec-
tive in treating patients with lymphoma and chronic
lymphocytic leukemia (CLL) [10-13]. CD19 CAR T cell
adoptive therapy has resulted in dramatic clinical
responses which have been associated with in vivo
expansion and long term persistence of the engineered
T cells. Some patients have experienced tumor lysis syn-
drome and prolonged depletion of B cells is common.
A clinical protocol that uses the autologous T cells
expressing CAR specific for the folate receptor -alpha
(FRa)[14] is being developed by University of Pennsylva-
nia investigators in cooperation with the National Can-
cer Institute (NCI) Cancer Immunotherapy Trial
Network (CITN). FRa is over expressed on the surface
of epithelial malignancies including ovarian, breast,
renal, colorectal, lung, and other solid cancers, but its
expression is limited on normal tissue. The protocol
involves adoptive cell therapy with genetically engi-
neered autologous T cells given to patients with ovarian
cancer following lymphodepletion alone or followed by
the administration of recombinant IL-7 and was rationa-
lized by the established role for IL-7 in maintaining T
cell memory and homeostasis, as well as initial observa-
tions by Powell et al. that transferred tumor antigen-
specific T cells dramatically up-regulate the IL-7 recep-
tor immediately after infusion [15].
Reprogramming cells
The reprogramming of adult cells in order to produce
more primitive cells or stem cells is becoming an impor-
tant part of cellular therapy of cancer. Adult cells can be
reprogrammed to produce induced pluripotent stem
cells (IPSC) which have properties similar to embryonic
stem cells. Investigators are now working to reprogram
T cells to produce “stem-like” T cells that are more
effective in adoptive cell therapy.
Induced pluripotent stem cells
Methods to reprogram stem cells have improved greatly
since Yamanaka first demonstrated that the transfer of 4
transcription factors, Oct4, Klf4, Sox2 and cMyc, into
fibroblasts can produce IPSCs [16]. IPSCs differ in some
respects from embryonic stem cells (ESCs) but these dif-
ferences can be reduced by removing the transcription
factor used for reprogramming. One method involves
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reprogramming using a single excisable lentivral vector
containing all 4 transcription factors which allows for
highly efficient reprogramming and IPSCs free of exo-
genous transgenes using from fresh and store blood
samples [17-19]. Traditional culture of IPSCs involves
the growth of cells on feeder cell layers or extracellular
matrix derived from animals and the use of media sup-
plemented with animal serum. Methods are being devel-
oped to produce and culture IPSC using xenogenic free
materials and reagents which will improve the safety of
these products. Companies are developing platforms for
high throughput IPSC generation. These platforms also
allow for cell maintenance and characterization.
Reprogramming T cells
Several studies have found that T cell phenotype affects
their effectiveness for adoptive cell therapy. Comparison
of TIL cells from patients responding to therapy and
those that did not has found that clinical responses
were associated with TIL that expressed co-stimulatory
molecules CD27 and CD28, have longer telomeres and
persist longer in vivo. Several investigators have been
exploring methods to produce cytotoxic T cells which
persist longer and are more effectively clinically [1].
Using CMV reactive T cells and a macaque model, Car-
olina Berger and Stan Riddell found that CMV-specific
effector CD8+ T cell (TE) populations derived from cen-
tral memory T cells (TCM) rather than effecter memory
T cells (TEM) retained the ability to survive long-term in
the circulation, bone marrow, and lymph nodes [20]. Of
note, the TCM-derived TE cells differentiated to both
TCM and TEM phenotypes in vivo and responded effi-
ciently to antigen challenge [20]. This work has recently
been extended to human virus-specific T cells [21].
A major new area reviewed at the meeting was the
idea that mature, post-thymic lymphocytes have stem
cell-like qualities. Restifo et al. have recently found that
Th17-polarized CD4+ T cells have stem cell-like quali-
ties. Th17 have superior anti-tumour activities than
their Th1 counterparts, are resistant to apoptosis and
persist long-term after adoptive cell transfer. Most
importantly, they have the stem cell-like properties of
self-renewal and multipotency [22].
In addition, Gattinoni et al. have identified a subpopu-
lation of circulating T cells with both naïve and memory
T cell properties with a CD45RO-, CCR7+, CD45RA+,
CD62L+, CD27+, CD28+ and IL-7Ra+ phenotype which
they have called stem central memory T (Tscm) cells
[23]. These T scm cells have greater proliferative poten-
tial, longer in vivo survival and are more potent for
adoptive cell transfer than naïve, central memory, effec-
tor memory or effector T cells [23,24].
While Tscm cells are potentially very effective in
adoptive cellular therapy, very few Tscm cells are
present in the circulation. Several laboratories have been
investigating methods to reprogram T cells in order to
produce the large quantities of Tscm cells that would be
needed for adoptive cell therapy. Wnt signaling/b-cate-
nin and mTor signaling pathways have been found to be
important in T cell maturation [25,26]. The Wnt/b-cate-
nin pathway is activated in naïve T cell, but becomes
progressively less active as T cells mature. Because the
Wnt/b-catenin pathway is important in cancer, a num-
ber of drugs are being developed that interact with this
pathway. Gattinoni et al. have found that Tscm cells can
be efficiently generated in vitro when naïve T cells are
stimulated in the presence of a Wnt pathway activator,
TWS119 [23,24]. In the future, it may be possible to use
similar methods to generate large quantities of Tscm
cells ex vivo for use in adoptive cell therapy coupling
TCR or CAR engineering with pharmacological modula-
tion of T cell differentiation.
Vaccine therapy using long peptides
An alternative to adoptive transfer of T cells is vaccination
with DCs loaded with short tumor peptides that bind
exactly to specific HLA epitopes, however the effectiveness
of these therapies have been limited by insufficiently con-
sistent and robust effector T cell responses. Vaccination
with longer tumor peptides (28-35 amino acids) results in
more efficient peptide processing and presentation than
short peptides. The treatment of 20 women with high
grade vulvar intraepithelial neoplasia with 3 subcutaneous
Human Papilloma Virus 16 (HPV 16) E6 and E7 synthetic
peptide vaccines resulted in clinical responses in 15 of 19
patients at 12 months of follow-up [27]. HPV 16-specific-
T cell responses were significantly greater in the group of
patients with complete regression of their lesions com-
pared to the non-responders.
NK cells
Autologous NK cells are being expanded ex vivo by 100-
1000 fold and used to treat patients with CLL, colon
cancer and renal cell carcinoma (RCC). Patients are first
treated with the proteasome inhibitor bortezomib to
increase tumor sensitivity to NK cell cytotoxicity
mediated by TNF-related apoptosis-inducing ligand
(TRAIL) prior to infusion of expanded autologous NK
cells with low dose subcutaneous IL-2 administered
twice daily for 1 week following infusion [28]. Phase I
dose escalation of increasing numbers of adoptively
transferred autologous NK cells continues, with 2 infu-
sions of up to a dose of 1 × 108 NK cells/kg having
already been established to be safe, with preliminary evi-
dence for anti-tumor effects being observed against
tumors such as RCC and CLL.
Allogeneic NK cells are being used to treat hematolo-
gical malignancies. These allogeneic NK cells protocols
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make use of in vivo expansion by using pretreatment
lymphoreduction therapy and post-infusion IL-2 therapy
[29]. As an alternative to IL-2, the CITN recently devel-
oped a clinical trial to test the safety and efficacy of out-
patient IL-15 therapy in order to stimulate NK and CD8
+ T cells. IL-15, compared to IL-2, may enhance cell-
based immunotherapy as it is hypothesized to have less
of an effect on suppressive regulatory T-cells that down-
regulate NK cell and T cell function. This may lead to
better clinical efficacy and has broad implications for
the field of immunotherapy.
Evaluation of biomarkers for adoptive cellular
therapies
A critical part of the treatment of cancer with adoptive
cellular therapies is the monitoring of recipients follow-
ing treatment. Clinical trials of cellular therapies for
cancer should include biomarker studies in an inte-
grated, quality, supported, and meta-analyzeable manner
[30]. For T cell therapy clinical trials, the biomarker
classes assessed should evaluate T cell presence, biologi-
cally relevant phenotypes and functions of the T cells, T
cell bioactivity, as well as recipient immune responses to
the infused T cells. Numerous approaches can be used
to evaluate each of these classes of biomarkers [31].
These principals were recently applied in a clinical trial
which treated CLLwith anti-CD19 T cells and this
approach provided a remarkable breadth and depth of
information concerning T cell persistence, phenotype,
and function [12,13].
Regulatory
Most clinical studies involving adoptive cellular thera-
pies are conducted under an Investigational New Drug
(IND) application. FDA encourages early preparation for
critical points in the IND process, such as moving into
initial clinical studies and transitioning to pivotal clinical
trials. Proper preparation allows for an easier transition,
a better designed study, and a higher likelihood of suc-
cess. FDA staff encourages sponsors and investigators to
take advantage of formal meetings, such as pre-IND
meetings, and is often willing to speak with sponsors
and investigators through direct informal interactions.
In addition, numerous FDA websites contain informa-
tion useful for investigators (http://www.fda.gov/biolo-
gicsbloodvaccines/newsevents/ucm232821.htm and
http://www.fda.gov/BiologicsBloodVaccines/Guidance-
ComplianceRegulatoryInformation/OtherRecommenda-
tionsforManufacturers/ucm094338.htm).
Conclusions
The field of adoptive cell therapy is advancing rapidly.
Conventional cellular therapies, such as TIL, are becom-
ing more effective and more available. Gene therapy is
becoming an important tool in adoptive cell therapy.
Autologous lymphocytes are being engineered to express
TCRs, CARs and cytokines. T cell subsets with more
naïve and stem cell-like characteristics have been shown
in pre clinical models to be more effective than unse-
lected populations. In the future combination of adop-
tive transfer of T cells and specific vaccination against
the cognate antigen can be envisaged to further enhance
the effectiveness of treatment.
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